Marker Therapeutics (MRKR) Cash from Financing Activities (2010 - 2025)
Marker Therapeutics (MRKR) posted quarterly Cash from Financing Activities of $9.9 million for Q3 2025, up 579787.3% year-over-year from N/an in Q3 2024, and up 9863783.0% quarter-over-quarter from $100.0 in Q2 2025.
Marker Therapeutics (MRKR) Cash from Financing Activities (2010 - 2025) Analysis & Trends
Marker Therapeutics (MRKR) has reported Cash from Financing Activities for 16 consecutive years, with $9.9 million the latest figure, recorded in Q3 2025.
- In Q3 2025, Cash from Financing Activities rose 579787.3% year-over-year to $9.9 million; the TTM figure through Dec 2025 stood at $9.9 million (down 34.2% YoY), while the FY2025 annual figure was $9.9 million, down 34.2% from the prior year.
- Cash from Financing Activities advanced to $9.9 million in Q3 2025 per MRKR's latest filing, from $100.0 in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $52.7 million in Q1 2021 and bottomed at -$100743.0 in Q2 2021.
- Historically, Cash from Financing Activities has averaged $5.2 million across 5 years, with a median of $49096.0 in 2024.
- On a YoY basis, Cash from Financing Activities climbed as much as 579787.3% in 2025 and fell as far as 99.78% in 2025.
- Marker Therapeutics' Cash from Financing Activities stood at -$100743.0 in 2021, then soared by 237.41% to $138427.0 in 2022, then sank by 96.29% to $5135.0 in 2023, then soared by 289985.9% to $14.9 million in 2024, then tumbled by 33.78% to $9.9 million in 2025.
- Business Quant data shows MRKR's Cash from Financing Activities at $9.9 million in Q3 2025, $100.0 in Q2 2025, and $505.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 14.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -6.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 36.24 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -16.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 27.18 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -273.15 Mn |
| 10 | Marker Therapeutics | 27.04 Mn | 15.11 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 9.86 Mn |
| Sep 30, 2025 | 9.86 Mn |
| Jun 30, 2025 | 100.00 |
| Jun 30, 2025 | 100.00 |
| Mar 31, 2025 | 505.00 |
| Mar 31, 2025 | 505.00 |
| Dec 31, 2024 | 14.90 Mn |
| Dec 31, 2024 | 14.90 Mn |
| Sep 30, 2024 | 1,701.00 |
| Sep 30, 2024 | 1,701.00 |
| Jun 30, 2024 | 44,606.00 |
| Jun 30, 2024 | 44,606.00 |
| Mar 31, 2024 | 49,096.00 |
| Mar 31, 2024 | 49,096.00 |
| Dec 31, 2023 | 5,135.00 |
| Dec 31, 2023 | 5,135.00 |
| Sep 30, 2023 | 479,272.00 |
| Sep 30, 2023 | 479,272.00 |
| Jun 30, 2023 | 736.00 |
| Jun 30, 2023 | 736.00 |